Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) will release its fiscal 2022 first quarter financial results on February 10, 2022, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results, which will also be available via webcast. Applied DNA specializes in PCR-based DNA manufacturing and nucleic acid technologies, including its proprietary LinearDNA platform used in diagnostics and drug development. Visit adnas.com for more details.
- Applied DNA is advancing its LinearDNA technology for large-scale PCR-based DNA manufacturing.
- The upcoming financial results may provide insight into the company's growth in the nucleic acid-based diagnostics and drug development markets.
- None.
Conference Call and Webcast Information - Live
Date: |
|
|||
Dial in: |
844-887-9402 |
|||
|
412-317-6798 (international) |
|||
Hosts: |
Dr. |
|||
|
|
|||
Webcast: |
https://services.choruscall.com/mediaframe/webcast.html?webcastid=fG5RNOCf |
Conference Call and Webcast Information - Replay
A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.
Dial in: |
877-344-7529 |
||
|
412-317-0088 (international) |
||
|
Access Code: 2723913 |
||
Webcast: |
https://services.choruscall.com/mediaframe/webcast.html?webcastid=fG5RNOCf |
||
Availability: |
Telephonic replay: until |
About
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a high-throughput turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005647/en/
Investor Relations:
Web: www.adnas.com
Twitter: @APDN
Source:
FAQ
When will Applied DNA Sciences report its first quarter financial results for 2022?
What time is the conference call for Applied DNA Sciences' financial results?
What is the ticker symbol for Applied DNA Sciences?
What technology does Applied DNA specialize in?
